Equities
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)194.55
  • Today's Change2.10 / 1.09%
  • Shares traded140.31k
  • 1 Year change+27.74%
  • Beta1.7114
Data delayed at least 15 minutes, as of Nov 22 2024 10:28 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 18-Nov-24
Select bar for recommendation details.
Recommendations18-Nov-24
Buy3
Outperform2
Hold1
Sell0
Strong Sell0

Share price forecast in DKK

The 6 analysts offering 12 month price targets for Bavarian Nordic A/S have a median target of 315.00, with a high estimate of 375.00 and a low estimate of 245.00. The median estimate represents a 63.68% increase from the last price of 192.45.
High94.9%375.00
Med63.7%315.00
Low27.3%245.00

Earnings history & estimates in DKK

On Nov 15, 2024, Bavarian Nordic A/S reported 3rd quarter 2024 earnings of 0.90 per share.
The next earnings announcement is expected on Mar 05, 2025.
Bavarian Nordic A/S reported annual 2023 earnings of 19.20 per share on Mar 06, 2024.
Average growth rate+33.78%
More ▼

Revenue history & estimates in DKK

Bavarian Nordic A/S had 3rd quarter 2024 revenues of 1.36bn. This missed the 1.62bn consensus estimate of the 2 analysts following the company. This was 8.89% above the prior year's 3rd quarter results.
Average growth rate+20.34%
Bavarian Nordic A/S had revenues for the full year 2023 of 7.06bn. This was 124.14% above the prior year's results.
Average growth rate+93.06%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.